Epidermal Growth Factor Signaling Pathway and Molecular Oncology

Course Logistics and Administrative Information

  • Lecture Date: September 23, 2026.

  • Discussions: Scheduled for this week and next week.

  • Homework: Problem sets posted later today.

  • Review Sessions:

    • General Review Session: Thursday, September 24, 2026, at 7:00 PM in Mahar Auditorium.

    • Exam 1 Review Session: Wednesday, September 20, 2026, at 7:00 PM in Mahar Auditorium.

  • Exam 1 Details:

    • Date & Time: Thursday, October 1, 2026, from 7:00 PM to 9:00 PM.

    • Duration: Exam is written to be comfortably completed in 11  hour, but 22  hours are provided.

    • Practice Exam: Posted over the weekend.

    • Exam Room Assignments (by Last Name):

    • A – Orsman: Mahar Auditorium

    • Orsman – White: Morrill N375

    • Williams – Z: Morrill 319

    • BioPioneers: Morrill N326

Spindle Assembly Checkpoint and Anaphase Progression

Spindle Assembly Checkpoint Pathway
  • Molecular Mechanism of Mitotic Control:

    1. Checkpoint Activation: Unattached kinetochores release chemical signals that cause MAD\text{MAD} to bind CDC20\text{CDC20}.

    2. Kinetochore Attachment: Once all kinetochores are properly attached to spindle fibers, MAD\text{MAD} releases CDC20\text{CDC20}, which then combines with the Anaphase-Promoting Complex (APC\text{APC}).

    3. Ubiquitination: The active APC/CDC20\text{APC/CDC20} complex ubiquitinates Securin\text{Securin}.

    4. Proteolysis: Securin\text{Securin} is destroyed via proteasomal degradation, releasing the active enzyme Separase\text{Separase}.

    5. Cleavage of Cohesin: Separase\text{Separase} cleaves and destroys Cohesin\text{Cohesin}, the protein complex holding sister chromatids together.

    6. Anaphase Onset: Sister chromatids separate, and mitosis proceeds to anaphase.

Kinase Cascade Dynamics and Regulation

Kinase Cascade Signaling
  • General Kinase Cascade Architecture:

    • Extracellular signal binds to Receptor (R\text{R}).

    • Activated Receptor phosphorylates Target Kinase 1 (TK1\text{TK}_1).

    • Active TK1\text{TK}_1 phosphorylates Target Kinase 2 (TK2\text{TK}_2).

    • Active TK2\text{TK}_2 phosphorylates Transcription Factor (TFa\text{TF}_a).

    • Phosphorylated TFa\text{TF}_a activates RNA Polymerase (RNAP\text{RNAP}) to transcribe target genes.

  • Phosphatase Deactivation and Protein Turnover:

    • A phosphatase targeting TK2\text{TK}_2 turns TK2\text{TK}_2 off immediately by removing its phosphate group.

    • TFa\text{TF}_a remains active (TFa-PO4\text{TF}_a\text{-PO}_4) until natural protein turnover degrades the phosphorylated copies.

    • New TFa\text{TF}_a molecules are synthesized in an unphosphorylated (inactive) state.

    • Without active TFa\text{TF}_a, gene expression for the phosphatase ceases, and existing phosphatase proteins gradually disappear via standard protein turnover.

  • Crosstalk and Pathway Regulation:

    • Signaling pathways can intersect, where components of Pathway XX (1x→2x→TFx1x \rightarrow 2x \rightarrow \text{TF}_x) regulate Pathway YY (1y→2y→TFy1y \rightarrow 2y \rightarrow \text{TF}_y), modulating expression between specific target gene sets (e.g., Light Genes vs. Other Genes).

Epidermal Growth Factor Receptor (EGFR) Architecture

EGFR Binding and Structural Conformation
  • Receptor Structure:

    • EGFR\text{EGFR} (also designated HER1\text{HER1} or ErbB1\text{ErbB1}) is a Receptor Tyrosine Kinase (RTK\text{RTK}) spanning the cell membrane.

    • Extracellular Domain: Composed of four distinct domains:

    • Domain I and Domain III: Closely related in sequence; participate directly in ligand binding.

    • Domain II and Domain IV: Closely related in sequence; contain structural loops including the domain II dimerization arm.

    • Cytoplasmic Domain: Contains an intrinsic protein tyrosine kinase catalytic core, a juxtamembrane segment, and a C-terminal tail with key tyrosine residues (Y845\text{Y845}, Y992\text{Y992}, Y1045\text{Y1045}, Y1068\text{Y1068}, Y1086\text{Y1086}, Y1148\text{Y1148}, Y1173\text{Y1173}).

  • Conformational Switching and Dimerization:

    • Tethered Inactive Conformation: In the absence of ligand, EGFR\text{EGFR} exists as a monomer. The β\beta-hairpin dimerization arm of domain II intramolecularly binds to domain IV, preventing dimerization.

    • Ligand Binding: Ligand binding (e.g., EGF\text{EGF}, TGF-α\text{TGF-}\alpha, HB-EGF\text{HB-EGF}, Amphiregulin/AREG\text{AREG}, Epiregulin/EREG\text{EREG}, Epigen/EPGN\text{EPGN}, Betacellulin/BTC\text{BTC}) occurs simultaneously across domains I and III.

    • Un-tethering: Binding induces a structural reorganization that extends the extracellular region, exposing the domain II dimerization arm.

    • Dimerization: Two ligand-bound monomers dimerize through reciprocal interactions between exposed dimerization arms.

  • Asymmetric Kinase Activation:

    • Dimerization brings cytosolic kinase domains into proximity, forming an asymmetric kinase domain dimer.

    • The C-lobe of the Donor Kinase docks against the N-lobe of the Acceptor Kinase.

    • This physical interaction pushes the acceptor kinase's activation loop out of its catalytic active site, allowing ATP\text{ATP} and protein substrates to bind.

    • The activated acceptor kinase then transphosphorylates specific tyrosine residues on the C-terminal tails of both receptor subunits.

The Ras/RAF/MEK/ERK (MAPK) Pathway Cascade

EGFR Signaling Cascade to MAPK
  • Nomenclature and Biochemical Functions:

    • EGF\text{EGF}: Epidermal Growth Factor (Extracellular signal ligand).

    • EGFR\text{EGFR}: Epidermal Growth Factor Receptor (Receptor Tyrosine Kinase).

    • GRB2\text{GRB2}: Growth Factor Receptor-Bound Protein 2 (Adapter protein containing one SH2\text{SH2} domain and two SH3\text{SH3} domains).

    • SOS\text{SOS}: Son of Sevenless (Guanine Nucleotide Exchange Factor, or Ras-GEF\text{Ras-GEF}).

    • Ras\text{Ras}: Rat Sarcoma Virus Protein (Small monomeric GTPase tethered to the inner leaflet of the plasma membrane via a C-terminal lipid modification).

    • NF1\text{NF1}: Neurofibromin 1 (GTPase Activating Protein, or Ras-GAP\text{Ras-GAP}).

    • RAF\text{RAF}: Rapidly Accelerated Fibrosarcoma Kinase (MAP3K\text{MAP3K} / Serine/Threonine Kinase).

    • MEK\text{MEK}: Mitogen-Activated Protein Kinase Kinase (MAP2K\text{MAP2K} / Dual-specificity Kinase).

    • MAPK (ERK)\text{MAPK (ERK)}: Mitogen-Activated Protein Kinase / Extracellular Signal-Regulated Kinase (MAPK\text{MAPK}).

  • Step-by-Step Activation Sequence:

    1. Ligand Binding & Autophosphorylation: EGF\text{EGF} binds EGFR\text{EGFR}, driving dimerization and trans-autophosphorylation of cytosolic tyrosine residues.

    2. Adapter Recruitment: Phosphotyrosines on EGFR\text{EGFR} serve as high-affinity docking sites for the SH2\text{SH2} domain of GRB2\text{GRB2}.

    3. GEF Translocation: GRB2\text{GRB2} uses its SH3\text{SH3} domains to bind proline-rich regions on SOS\text{SOS}, recruiting SOS\text{SOS} from the cytoplasm to the membrane.

    4. Ras Activation: Membrane-bound SOS\text{SOS} acts on inactive Ras-GDP\text{Ras-GDP}, promoting the release of GDP\text{GDP} and binding of abundant cellular GTP\text{GTP} to generate active Ras-GTP\text{Ras-GTP}.

    5. RAF Recruitment: Active Ras-GTP\text{Ras-GTP} binds directly to the Ras Binding Domain (RBD\text{RBD}) of RAF\text{RAF}.

    6. RAF Activation: Binding to Ras-GTP\text{Ras-GTP} brings RAF\text{RAF} to the plasma membrane and relieves its autoinhibition. RAF\text{RAF} activation is mediated by conformational change upon binding Ras\text{Ras}, not by direct phosphorylation.

    7. Phosphorylation Cascade:

    • Active RAF\text{RAF} phosphorylates MEK\text{MEK} on serine/threonine residues, activating MEK\text{MEK}.

    • Active MEK\text{MEK} phosphorylates ERK\text{ERK} on threonine and tyrosine residues (T202/Y204\text{T202/Y204}), activating ERK\text{ERK}.

    1. Nuclear Translocation: Active, phosphorylated ERK\text{ERK} translocates from the cytoplasm into the nucleus.

    2. Transcriptional Activation: ERK\text{ERK} phosphorylates nuclear transcription factors (e.g., ELK-1\text{ELK-1}, c-MYC\text{c-MYC}, c-JUN\text{c-JUN}, c-FOS\text{c-FOS} / AP-1 Complex), stimulating expression of genes such as Cyclin D1, which drives progression from G1\text{G}_1 to S\text{S} phase in the cell cycle.

  • Parallel EGFR Signaling Pathways:

    • PI3K/AKT\text{PI3K/AKT} Pathway: EGFR\text{EGFR} activates PI3K\text{PI3K} (via p85/p110\text{p85/p110} or GAB1\text{GAB1}), converting PIP2\text{PIP}_2 to PIP3\text{PIP}_3. PDK1\text{PDK1} phosphorylates AKT\text{AKT}, which inhibits TSC1/2\text{TSC1/2} to activate mTORC1\text{mTORC1}. This pathway blocks apoptosis, promotes cell survival, cell growth, angiogenesis, and migration.

Molecular Regulation of G-Proteins

G-Protein Molecular Switch Cycle
  • Chemical Structures of Nucleotides:

    • GDP\text{GDP}: Guanine-nucleotide Di-Phosphate (contains two phosphate groups attached to ribose and guanine base).

    • GTP\text{GTP}: Guanine-nucleotide Tri-Phosphate (contains three phosphate groups attached to ribose and guanine base).

  • Regulatory Proteins:

    • GEF\text{GEF} (Guanine Nucleotide Exchange Factor):

    • Function: Catalyzes the release of GDP\text{GDP} from Ras\text{Ras}, allowing GTP\text{GTP} to enter the binding pocket, converting Ras\text{Ras} to its active state.

    • Human Ras-GEF\text{Ras-GEF}: SOS\text{SOS}.

    • Functional State: GEF = ON\text{GEF = ON} switch.

    • GAP\text{GAP} (GTPase Activating Protein):

    • Function: Stimulates the intrinsic GTPase activity of Ras\text{Ras}, enhancing the rate of GTP\text{GTP} hydrolysis into GDP+Pi\text{GDP} + \text{P}_i, converting Ras\text{Ras} back to its inactive state.

    • Human Ras-GAP\text{Ras-GAP}: NF1\text{NF1} (Neurofibromin 1).

    • Functional State: GAP = OFF\text{GAP = OFF} switch.

  • GTP Hydrolysis Reaction Equation:   GTP+H2O→GDP+Pi\text{GTP} + \text{H}_2\text{O} \rightarrow \text{GDP} + \text{P}_i

  • Dual Functions of Ras:

    1. RAF Activation: Requires GTP\text{GTP} bound to Ras\text{Ras}.

    2. Intrinsic GTPase Activity: Hydrolyzes GTP\text{GTP} to GDP\text{GDP} to shut itself off.

  • Timeline of Functional States:

    • Pre-signaling: Ras\text{Ras} bound to GDP\text{GDP}. RAF\text{RAF}-activating activity is OFF; GTPase activity is OFF.

    • Signal On: EGFR\text{EGFR} activation recruits SOS\text{SOS}, exchanging GDP\text{GDP} for GTP\text{GTP}. RAF\text{RAF}-activating activity turns ON.

    • Signal Off: NF1\text{NF1} (GAP\text{GAP}) binds Ras-GTP\text{Ras-GTP}, triggering intrinsic GTPase activity. GTP\text{GTP} is hydrolyzed to GDP\text{GDP}, turning RAF\text{RAF}-activating activity OFF. GAP\text{GAP} activity is brief and terminates once GDP\text{GDP} is formed.

EGFR Endocytosis and Attenuation

  • Endocytic Trafficking Modes:

    • Induction: EGF\text{EGF} binding and receptor activation stimulate Clathrin\text{Clathrin} proteins to assemble a cage-like structure around the receptor-containing membrane regions, forming Clathrin-coated pits that pinch off into vesicles and travel to the endosome.

    • Recycling Mode: The receptor-ligand complex dissociates in acidic endosomes; phosphates are removed, and receptors are returned to the cell membrane to function again.

    • Destruction Mode: Receptors are routed to lysosomes (the vesicular functional equivalent of the proteasome) where both ligand and receptor proteins are degraded, downregulating receptor density on the cell surface.

  • Receptor Expression Density and Dimerization Behavior:

    • Normal Cells: Express approximately 50,00050,000 EGF\text{EGF} receptors on their cell surface.

    • HER2+\text{HER2+} Cancer Cells: Overexpress HER2\text{HER2} to levels exceeding 1,000,0001,000,000 receptors per cell.

    • Structural Unique Feature of HER2\text{HER2}: HER2\text{HER2} (ErbB2\text{ErbB2}) cannot directly bind EGF\text{EGF} or any known soluble ligand because its extracellular binding pocket is closed. However, its domain II dimerization arm is constitutively exposed ("lifted").

    • Heterodimerization: HER2\text{HER2} heterodimerizes with ligand-bound EGFR\text{EGFR} or HER3\text{HER3} at extremely low concentrations of EGF\text{EGF}, activating strong downstream signals.

    • Homodimerization: At hyper-dense levels (>1,000,000> 1,000,000 receptors/cell), HER2\text{HER2} monomers spontaneously encounter each other and form HER2/HER2\text{HER2/HER2} homodimers, activating MAPK\text{MAPK} signaling completely independent of EGF\text{EGF} signal.

Therapeutic Targets and Inhibitory Strategies

EGFR Pathway Inhibitor Targets
  • Targeted Pharmacological Inhibitors:

    • Herceptin (Trastuzumab): Monoclonal antibody targeting the extracellular domain of HER2\text{HER2}. Inhibits both homodimerization and heterodimerization of HER2\text{HER2}.

    • Clinical Efficacy: Improves 5-year disease-free survival from 75.4%75.4\% to 87.1%87.1\% (P<0.0001P < 0.0001, Hazard Ratio 0.480.48); improves overall survival with Hazard Ratio 0.670.67 (P=0.015P = 0.015).

    • Tarceva (Erlotinib): Small molecule inhibitor blocking the cytosolic ATP-binding kinase domain of EGFR\text{EGFR}.

    • Daraxonrasib: Small molecule inhibitor directly targeting Ras\text{Ras}.

    • Vemurafenib: Specific kinase inhibitor targeting active RAF\text{RAF}.

    • Selumetinib: Specific kinase inhibitor targeting active MEK\text{MEK}.

    • Beroterkib: Specific kinase inhibitor targeting active ERK\text{ERK}.

  • Conceptual Analysis of Pathway Mutations (Cancer Mechanisms vs. Inhibition):

    • Mutations that increase pathway signaling and promote cancer:

    • Loss-of-function mutation in NF1\text{NF1} (Ras-GAP\text{Ras-GAP}).

    • Point mutations blocking the intrinsic GTPase activity of Ras\text{Ras}.

    • Constitutively active SOS\text{SOS} (Ras-GEF\text{Ras-GEF}).

    • Mutations in EGFR\text{EGFR} driving receptor dimerization/kinase activity without ligand.

    • Amplification/over-expression of EGFR\text{EGFR} or HER2\text{HER2} genes.

    • Constitutively active RAF\text{RAF} or MEK\text{MEK} kinase domain activity.

    • Unphosphorylated ERK\text{ERK} gaining aberrant nuclear entry.

    • Strategies that block hyperactive pathway signaling:

    • Blocking dimerization using Herceptin\text{Herceptin}.

    • Pharmacological inhibition of EGFR\text{EGFR} tyrosine kinase activity (Tarceva\text{Tarceva}).

    • Blocking the Ras\text{Ras}-binding domain (RBD\text{RBD}) on RAF\text{RAF} to prevent RAF-Ras\text{RAF-Ras} contact.

    • Direct inhibition of RAF\text{RAF}, MEK\text{MEK}, or ERK\text{ERK} kinase domains.